中国抗肿瘤治疗相关恶心呕吐预防和治疗指南(2023版)
中国抗癌协会多个专业委员会与中国临床肿瘤学会专家整合近年抗肿瘤治疗相关恶心呕吐防治新进展,遵循循证医学证据并参考国内外指南和国内临床实践,共同制定本指南,为中国抗肿瘤治疗相关恶心呕吐的预防和治疗提供专业指导。
要点
- 中国恶性肿瘤年龄标化死亡率下降,综合防控成效显著。
- 恶心呕吐是抗肿瘤治疗常见不良反应,影响生活质量并可能限制疗效。
- 本指南整合新进展、循证证据与国内外指南及国内实践制定。
核心结论
- 本指南旨在为中国抗肿瘤治疗相关恶心呕吐的预防和治疗提供专业指导意见。
研究设计与样本
- 由中国抗癌协会癌症康复与姑息治疗专业委员会、肿瘤临床化疗专业委员会、肿瘤支持治疗专业委员会及中国临床肿瘤学会肿瘤支持与康复治疗专家委员会专家共同制定。
- 制定方法为整合近年抗肿瘤治疗相关恶心呕吐防治新进展,遵循现有循证医学证据,参考国内外指南并结合国内临床实践经验。
主要发现
- 中国恶性肿瘤发病率和死亡率呈上升趋势,但年龄标化死亡率出现下降。
- 年龄标化死亡率下降表明通过危险因素防控、肿瘤筛查、早诊早治、规范化诊疗等措施,中国在肿瘤综合预防和控制方面取得显著成效。
- 新的抗肿瘤治疗方案和药物不断开发,但抗肿瘤治疗相关恶心呕吐仍是常见不良反应。
- 恶心呕吐对患者生活质量带来负面影响,并可能影响抗肿瘤治疗效果。
临床怎么用
- 本指南为中国抗肿瘤治疗相关恶心呕吐的预防和治疗提供专业指导意见。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Epidemiologic data show that the incidence and mortality of cancer in China has been increasing, but the age-standardized mortality rate (ASMR) decreased. The descend trend in ASMR indicated that China has achieved remarkable results in the comprehensive prevention and control of cancer in recent decades through the risk factor control, cancer screening, early diagnosis and treatment, and standardization of diagnostic and therapeutic protocols. In recent years, new anti-tumor therapies and drugs have been developed, but nausea and vomiting are still common adverse event associated with many anti-tumor therapies and can negatively impact patients' quality of life and potentially limit the effectiveness of anti-tumor therapies. The experts from China Anti-Cancer Association Committee of Rehabilitation and Palliative Care, China Anti-Cancer Association Committee of Tumor Clinical Chemotherapy, China Anti-Cancer Association Committee of Neoplastic Supportive-care and Chinese Society of Clinical Oncology Committee of Supportive and Rehabilitative Care have integrated recent advances in the prevention and treatment of nausea and vomiting caused by anti-tumor therapy. Following the existing evidence in evidence-based medicine, referring to both domestic and international guidelines, and considering the clinical practice in China, the "Guidelines for China prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)," has been formulated, aiming to provide professional guidance for the prevention and treatment of chemotherapy-induced nausea and vomiting in anti-tumor therapy in China. 流行病学数据显示,中国恶性肿瘤发病率和死亡率呈上升趋势,但年龄标化死亡率出现下降,年龄标化死亡率的下降证明几十年来中国通过开展危险因素防控、恶性肿瘤筛查、早诊早治、规范化诊疗等措施,在肿瘤综合预防和控制方面取得显著成效。近年来,新的抗肿瘤治疗方案和药物不断开发,但抗肿瘤治疗相关的恶心呕吐仍然是常见不良反应。恶心呕吐不仅会对患者生活质量带来负面影响,还有可能影响抗肿瘤治疗效果。由中国抗癌协会癌症康复与姑息治疗专业委员会、中国抗癌协会肿瘤临床化疗专业委员会、中国抗癌协会肿瘤支持治疗专业委员会、中国临床肿瘤学会肿瘤支持与康复治疗专家委员会专家整合近年来抗肿瘤治疗相关恶心呕吐预防和治疗新进展,遵循现有循证医学证据,参考国内外指南,结合国内临床实践经验,共同制定了中国抗肿瘤治疗相关恶心呕吐预防和治疗指南(2023版),以期为中国抗肿瘤治疗相关恶心呕吐预防和治疗提供专业指导意见。.
引用
- [China guidelines on prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)]. Zhonghua Zhong Liu Za Zhi. 2024. PMID: 38679793. doi:10.3760/cma.j.cn112152-20240123-00046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。